medigraphic.com
ISSN 0210-5187 (Digital)

2008, Número 3

<< Anterior Siguiente >>

Med Cutan Iber Lat Am 2008; 36 (3)


Aspectos imunopatológicos do vitiligo

Pereira AD, Lima FA, Cunha JMT

Idioma: Portugués
Referencias bibliográficas: 96
Paginas: 125-136
Archivo PDF: 200.81 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bellet JS, Prosen NS. Vitiligo em crianças: uma revisão de classificação, hipóteses sobre patogênese e tratamento. An Bras Dermatol 2005;80:565-712.

  2. Grimes PE. White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. J Am Acad Dematol 2004;51:s5-s7.

  3. Le Poole IC, Wañkowicz-Kaliñska A, Van den Wijngaard RM, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Invest Dermatol 2004;9:68-72.

  4. Gunduz K, Ozturk G, Terzioglu E, Sebik F. T cell subpopulations and IL-2R in vitiligo. J Dermatol 2004;31:94-7.

  5. Bystryn JC. Immune mechanisms in vitiligo. Clin Dermatol 1997;15:853-61.

  6. Al’Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-5.

  7. Picardo M. Oxidative stress in vitiligo, 2003. International Symposium on Vitiligo: “Vitiligo from Gene to Clinic: New Insights in Research and Treatment”. Royal College of physicians, London, 2003. Disponível em: < www.vitiligosociety.org.uk > . Acesso em 15 jan.2006.

  8. Gauthier Y, André MC, Taieb A. A Critical Appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-32.

  9. Abbas AK, Lichtman AH. Cellular and Molecular Immunology. 5th edition. Philadelphia: Saunders, 2003.

  10. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001;34:65-77.

  11. Castanet J, Ortonne JP. Immunology of vitiligo in: Skin Immune System (SIS). 2nd Ed. by Jan D. Bos. Boca Raton/New York: CRC Press, 1997.

  12. Lamont SJ, Smyth JR. Effect of bursectomy on development of a spontaneous postnatal amelanosis. Clin Immunol Pathol, v.21:407, 1981 In: Castanet, J.; Ortonne, J.P. Immunology of vitiligo in: Skin Immune System (SIS). 2nd Ed. by Jan D. Bos. Boca Raton/New York: CRC Press, 1997.

  13. Austin LM, Boissy RE, Jacobsen BS. The detection of melanocytes autoantibodies in the Smyth chicken model for vitiligo. Clin Immunol Immunopathol 1992;64:112-20.

  14. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. Science 1999;286:958-61.

  15. Robert C, Kupper TS. Inflammatory skin diseases, T cells and immune surveillance. N Eng J Med 1999;341:1817-28.

  16. Santamaria-Babí LF. CLA+ T cells in cutaneous diseases. Eur J Dermatol 2004;14:13-8.

  17. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skinhoming T cells. Nature 1997;389:978-81.

  18. Hunger RE, Yawalkar N, Braathen LR, Brand CU.The HECA-452 epitope is highly expressed on lymph cells derived from humam skin. Br J Dermatol 1999;141:565-9.

  19. Sigmundsdottir H, Gudjonsson JE, Valdimarsson H. The effects of ultraviolet B treatment on the expression of adhesion molecules by circulating T lymphocytes in psoriasis. Br J Dermatol 2003;148:996-1000.

  20. Van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das PK. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the proeminent presence of CLA+T cells at the perilesional site. Laboratory Investigation 2000;80:1299-309.

  21. Van den Wijngaard R, Aten J, Scheepmaker A, Le Poole IC, Tigges AJ, Westerhof W, Das PK. Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 2000;143:573-81.

  22. Dimitroff CJ, Kupper TS, Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003;112:1008-18.

  23. Grimes PE, Halder RM, Jones C, Chakrabarti SG, Enterline J, Minus HR, Kenney JA Jr. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983;119:300-3.

  24. Oppezzo P, Dighiero G. Autoantibodies, tolerance and autoimmunity. Pathol Biol (Paris) 2003;51:297-304.

  25. Ortonne JP, Bahadoran P, Fitzpatrick TB, Mosher DB, Hori Y. Hypomelanoses and Hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, editors. Fitzpatrick’s Dermatology in General Medicine. 6th Ed. New York: McGraw Hill 2003, pp. 839-47.

  26. Morgan M, Castells A, Ramírez A. Anticuerpos en vitiligo. Significado clínico. Med Cut ILA 1986;14:139-42.

  27. Mandry RC, Ortíz LJ, Lugo-Somolinos A, Sánchez JL. Organ-specific autoantibodies in vitiligo patients and their relatives. Int J Dermatol 1996;35:18-21.

  28. Kurtev A, Dourmishev AL. Thyroid function and autoimmunity in children and adolescents with vitiligo. JEADV 2004;18:109-11.

  29. Grimes PE. Forum 548: Vitiligo, 2006. American Academy of Dermatology 64th Annual Meeting, San Francisco, CA. disponível em: >Acesso em 20 mar. 2006.

  30. Sehgal V, Srivastava G. Vitiligo: auto-immunity and immune responses. Int J Dermatol 2005;45:583-90.

  31. Ongenae K, Geel NV, Naeyaert J-M. Evidence for autoimmune pathogenesis of vitiligo. Pigmented Cell Res 2003;16:90-100.

  32. Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Ferrone S et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993;72:2365-9.

  33. FISHMAN P. Autoantibodies to tyrosinase. Cancer 1997;79:1461-4.

  34. Naughton G, Reggiardo D, Bystryn J. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-81.

  35. Farrokhi S, Hojjat-Farsangi M, Noohpisheh MK, Tahmasbi R, Rezaei N. Assessment of the immune system in 55 Iranian patients with vitiligo. JEADV 2005;19:706-11.

  36. Gilhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995;105:683-6.

  37. Cui J, Arita Y, Bystryn JC. Cytolytic antibodies to melanocytes in vitiligo. J Investigative Dermatol 1993;100:812-5.

  38. Cui J, Chen D, Misfeldt ML, Swinfard RW, Bystryn JC. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995;8:60-3.

  39. Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrud B, Yecheskel G et al. Tyrosinase as an autontigen in patients with vitiligo. Clin Exp Immunol 1996;105:84-8.

  40. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS. Anti-tyrosinaserelated protein-2 immune response in vitiligo and melanoma patients receiving activespecific immunotherapy. J Invest Dermat 1998;111:1034-9.

  41. Xie Z, Chen D, Jiao D, Bystryn JC. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol 1999;135:417-22.

  42. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N. The role of tyrosinase in autoimmune vitiligo. Lancet 1994;344:1049-59.

  43. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Identification of epitopes on tyrosinase which are recognized by autoantibodies from patients with vitiligo. J Invest Dermatol 1999;113:267-71.

  44. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998; 139:798-805.

  45. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998;114:333-8.

  46. Kemp EH, Waterman EA, Hawes BE, O’Neill K, Gottumukkala RV, Gawkrodger DJ et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002;109:923-30.

  47. Waterman EA, Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. Clin Exp Immunol 2002;129:527-32.

  48. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody dependent cellular cytotoxicity (ADCC). J Invest Dermatol 1988;90:783-9.

  49. Le Poole IC, Van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996;148:1219-28.

  50. Goudie RB, Soukop M, Dagg JH, Lee FD. Hypothesis: symmetrical cutaneous lymphoma. Lancet 1990;335:316-8.

  51. Al Badri AM, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudie RB. An immunological study of cutaneous lymphocytes in vitiligo. J Pathol 1993;170:149-55.

  52. Le Poole IC, Das PK. Microscopic changes in vitiligo. Clinics in Dermatology 1997;15:863-73.

  53. Ahn SK, Choi EH, Lee SH, Won JH, Hann SK, Park YK. Immunohistochemical studies from vitiligo-comparision between active and inactive lesions. Yonsei Med J 1994;35:404-10.

  54. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M et al. Direct evidence to support the role of antigen-specific CD8+ T cells in melanoma-associated vitiligo. J Invest Dermatol 2001;117:1464-70.

  55. Barker JNWN, MacDonald DM. Cutaneous lymphocyte trafficking in the inflammatory dermatoses. Br J Dermatol 1992;126:211-5.

  56. Wan´kowicz-Kalin´ska A, Van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V et al. Immunopolarization of CD4+ and CD8+ T cells to type-1 like is associated with melanocyte loss in human vitiligo. Lab Invest 2003;83:683-95.

  57. Tu CX, Gu JS, Lin XR. Increased interleukin-6 and granulocyte-macrophage clony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Science 2003;31:73-8.

  58. Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo. J Dermatol 1990;17:287-96.

  59. Westerhof W, Groot I, Krieg SR, Bos JD, Cormane RH. Langerhan’s cells subpopulation studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venereol 1986;66:259-62.

  60. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987;123:1053-5.

  61. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins, self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol 2002;188:136-46.

  62. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T-cell mediated vitiligo. J Exp Med 2000;192:1637-43.

  63. Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR et al. Genetic vaccination with “self” tyrosinase —related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000;60:253-8.

  64. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan C et al. Vaccination with a recombinant vaccinia vírus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-7.

  65. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. New England J Med 2006;7:709-18.

  66. Lee D, Modlin RL. Breaking tolerance-another piece added to the vitiligo puzzle. J Investigative Dermatol 2004;124:1.

  67. Becker JC, Guldberg P, Zeuthen J, Bröcker EB, Straten PT. Accumulation of identical T cells in melanoma and vitiligo-like leucoderma. J Invest Dermatol 2002;113: 1033-8.

  68. Ortonne JP, Alario AT. T and B lymphocytes in vitiligo. Arch Derm Res 1978;261:147-51.

  69. Soubiran P, Benzaken S, Bellet C, Lacour JP, Ortonne JP. Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies. British J Dermatol 1985;113:124-7.

  70. D’amelio R, Frati C, Fattorossi A, Aiuti F Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives. Ann Allergy 1990; 65:143-5.

  71. Grimes PE, Ghoneum M, Stockton T, Payne C, Kelly AP, Alfred L. T-cell profiles in vitiligo. J Am Acad Dermatol 1986;14:196-201.

  72. Halder RM, Walters CS, Johnson BA, Chakrabarti SG, Kenney JA Jr. Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J Am Acad Dermatol 1986;14:733-7.

  73. Gunduz K, Ozturk G, Terzioglu E, Sebik F. T cell subpopulations and IL-2R in vitiligo. J Dermatol 2004;31:94-7.

  74. Kurtev A, Dourmishev AL. Thyroid function and autoimmunity in children and adolescents with vitiligo. JEADV 2004;18:109-11.

  75. Mozzanica N, Frigerio U, Finzi AF, Cattaneo A, Negri M, Scaglione F et al. T cell subpopulations in vitiligo: a chronobiologic study. J Am Acad Dermatol 1990;22:223-30.

  76. Abdel-naser M, Ludwig WD, Gollnick H, Orfanos CE. Nonsegmental vitiligo: decrease of the CD 45RA+ T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol 1992;31:321-6.

  77. Mahmoud F, Abul H, al-Saleh Q, Haines D, Burleson J, Morgan G. Peripheral T-cell activation in non-segmental vitiligo. The Journal of Dermatology 1998;25:637-40.

  78. Westermann J, Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 1990; 11:406-9.

  79. Hann SK, Park YK, Chung KY, Kim HI, Im S, Won JH. Peripheral blood lymphocyte imbalance in Koreans with active vitiligo. Int J Dermatol 1993;32:286-9.

  80. Honda Y, Okubo Y, Koga M. Relationship between levels of soluble interleukin-2 receptor and the types and activity of vitiligo. J Dermatol 1997;24:561-3.

  81. Galadari I. Serum level of the soluble interleukin-2 receptor in vitiligo patients in UAE. Allerg Immunol (Paris) 2005;37:109-11.

  82. Mantovani S, Garbelli S, Palermo B, Campanelli R, Brazzelli V, Borroni G et al. Molecular and functional bases of self-antigen recognition in Long-Term Persistent Melanocyte-Specific CD8+ T cells in one vitiligo patient. J Invest Dermatol 2003;121:308-14.

  83. Ogg GS et al. High frequency of skin-homing Melanocyte-specific Cytotoxic T lymphocytes in Autoimmune vitiligo. J Exp Med 1998; 188:1203-8.

  84. Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA. Cytotoxic T Lymphocyte Reactivity to gp100, Melan A/MART-1, and Tyrosinase, in HLA-A2 positive vitiligo patients. J Invest Dermatol 2003;121:550-6.

  85. Steitz J, Wenzel J, Gaffal E, Tüting T. Initiation and regulation of CD8+ T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of vitiligo. Eur J Cell Biol 2004;83:797-803.

  86. Steitz J, Brück J, Lenz J, Büchs S, Tüting T. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. J Invest Dermatol 2005;124:144-50.

  87. Durham-Pierre DG, Walters CS, Halder RM, Pham HN, Vanderpool EA. Natural Killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermat 1995;33:26-30.

  88. Mozzanica N, Villa ML, Foppa S, Vignati G, Cattaneo A, Diotti R, Finzi AF. Plasma alpha-melanocyte-stimulating hormone, betaendorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992;26:693-700.

  89. Yu HS, Chang KL, Yu CL, Li HF, Wu MT, Wu CS, Wu CS. Alterations in IL-6, IL-8, GM-CSF, TNF-alfa and IFN-gama release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997;108:527-9.

  90. Moellmann G, Klein-Angerer S, Scollay DA, Nordlund JJ, Lerner AB. Extracelular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982;79:321-30.

  91. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991;97:1081-5.

  92. Dell’Anna ML, Urbanelli S, Mastrofrancesco A, Camera E, Iacovelli P, Leone G et al. Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients. Pigment cell res 2003;16:553-9.

  93. Yildirim M, Baysal V, Inaloz HS, Can M The role of oxidants and antioxidants in generalized vitiligo at tissue level. J Eur Acad Dermatol Venereol 2004;18:683-6.

  94. Huang CL, Nordlund JJ, Boissy R. Vitiligo. A manifestation of apoptose. Am J Clin Dermatol 2002;3:301-8.

  95. Boissy RE, Liu YY, Medrano EE, Nordlund JJ Scructural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultured melanocytes from vitiligo patients. J Inves Dermat 1991;97:395.

  96. GauthierY, Muriel C, Taieb A. Melanocyte detachment after skin friction in non-lesional skin of patients with generalized vitiligo. Br J Dermatol 2003;148:95-101.




2020     |     www.medigraphic.com